emerg
infecti
diseas
recent
declar
pandem
current
vaccin
therapeut
avail
diseas
drug
reposit
repres
feasibl
option
address
global
challeng
panel
fdaapprov
drug
preselect
assay
sarscov
screen
identifi
potenti
antivir
drug
candid
infect
found
total
drug
exhibit
antivir
efficaci
ic
particular
two
fdaapprov
drug
niclosamid
ciclesonid
notabl
respect
drug
test
appropri
anim
model
antivir
activ
near
futur
alreadi
fdaapprov
drug
could
develop
follow
clinic
trial
order
provid
addit
therapeut
option
patient
authorfund
right
reserv
reus
allow
without
permiss
emerg
infecti
diseas
caus
novel
coronaviru
although
case
fatal
rate
due
viral
infect
vari
transmiss
rate
rel
high
recent
declar
outbreak
pandem
current
vaccin
therapeut
avail
patient
treat
support
care
drug
reposit
could
effect
strategi
respond
immedi
emerg
infecti
diseas
sinc
new
drug
develop
usual
take
year
fdaapprov
drug
provid
safe
altern
case
least
modest
antivir
activ
achiev
accordingli
sever
drug
test
numer
clinic
trial
includ
remdesivir
lopinavir
chloroquin
studi
screen
panel
fdaapprov
drug
identifi
antivir
drug
candid
treatment
suggest
identifi
drug
candid
may
consid
therapeut
develop
screen
approxim
fdaand
indapprov
drug
librari
sarscov
identifi
antivir
drug
candid
manuscript
prepar
sinc
sarscov
similar
sequenc
ident
drug
show
antivir
activ
sarscov
expect
show
similar
extent
antivir
activ
total
drug
select
earlier
sarscov
screen
result
addit
drug
includ
base
recommend
infecti
diseas
specialist
tabl
screen
experi
vero
cell
use
drug
ad
cell
prior
viru
infect
h
infect
infect
cell
score
immunofluoresc
analysi
antibodi
specif
viral
n
protein
confoc
microscop
imag
viral
n
protein
cell
nuclei
analyz
use
inhous
imag
mine
im
softwar
doserespons
curv
drc
drug
gener
figur
chloroquin
lopinavir
remdesivir
use
refer
drug
ic
valu
respect
figur
among
drug
evalu
studi
drug
show
potenti
antivir
activ
ic
valu
tiloron
cyclosporin
loperamid
mefloquin
amodiaquin
proscillaridin
digitoxin
digoxin
hexachlorophen
hydroxyprogesteron
caproat
salinomycin
ouabain
cepharanthin
ciclesonid
oxyclozanid
anidulafungin
gilteritinib
berbamin
tetrandrin
abemaciclib
ivacaftor
bazedoxifen
niclosamid
eltrombopag
among
drug
two
fdaapprov
drug
drew
attent
first
niclosamid
antihelminth
drug
exhibit
potent
antivir
activ
ic
surprisingli
broadspectrum
antivir
effect
well
document
second
ciclesonid
anoth
interest
drug
candid
develop
although
antivir
potenc
much
lower
ic
niclosamid
inhal
corticosteroid
use
treat
asthma
allerg
rhiniti
recent
report
matsuyama
et
al
corrobor
find
ciclesonid
potenti
antivir
drug
treatment
report
three
patient
infect
japan
http
warrant
clinic
investig
drug
patient
intriguingli
underli
mechan
suppress
viral
infect
ciclesonid
reveal
isol
drugresist
mutant
isol
drugresist
mutant
indic
viral
riboendonucleas
molecular
target
ciclesonid
togeth
unreason
consid
ciclesonid
exhibit
directact
antivir
activ
addit
intrins
antiinflammatori
function
futur
sirna
target
hormon
receptor
allow
assess
extent
directact
antivir
activ
proven
antiinflammatori
activ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
ciclesonid
may
repres
potent
drug
manifest
dual
role
antivir
antiinflammatori
control
infect
prior
evalu
drug
infect
also
test
antivir
activ
sever
drug
base
cytopath
effect
viru
presenc
drug
figur
particular
effect
favipiravir
atazanavir
compar
refer
drug
chloroquin
lopinavir
remdesivir
favipiravir
consid
drug
candid
clinic
trial
atazanavir
recent
predict
potent
antivir
drug
aiinfer
model
howev
current
work
observ
antivir
activ
either
favipiravir
atazanavir
summari
select
screen
fdaapprov
drug
base
sarscov
screen
screen
campaign
reveal
potenti
antivir
drug
candid
find
could
valid
appropri
anim
model
hope
develop
subsequ
clinic
trial
order
provid
addit
therapeut
option
patient
vero
cell
obtain
american
type
cultur
collect
atcc
reagent
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
tenpoint
drc
gener
drug
vero
cell
seed
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
